HOUSTON--(BUSINESS WIRE)--SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on the regrowth of the spinal disc nucleus using human dermal fibroblasts, announced the first injection of fibroblasts for the regeneration of the spinal disc. CybroCell is the first dermal fibroblast product for treatment of degenerative disc disease. The procedure was completed in less than 15 minutes using a local anesthetic. The patient experienced no complications and was discharged within an hour.
“This historic moment marks the first time a human patient has received dermal fibroblasts for treatment of degenerative disc disease,” said SpinalCyte Chief Executive Officer Pete O’Heeron. “Our preclinical trials resulted in significant regrowth of the spinal disc nucleus, increases in disc height, and gene expression such as proteoglycan with only one injection of fibroblasts. Using CybroCell, our off-the-shelf allogeneic dermal fibroblasts, we aim to build on our earlier clinical successes for treatment of degenerative disc disease.”
The clinical trial will enroll 18 patients between the ages of 18 and 85. Each patient will be administered CybroCell alone, in combination with platelet-rich plasma (PRP), or saline only. SpinalCyte aims to show that using its off-the-shelf, allogeneic “prepackaged” cell therapy product, CybroCell will lead to a reduction in pain, improved function, and regeneration of damaged discs.
“We believe this technology has the potential to emerge as the “first choice” cell-therapy option for spinal disc repair,” said Carlos Manuel Ruiz Macias, M.D., Principal Investigator of the SpinalCyte clinical trials. “CybroCell can offer a life-changing opportunity for millions of people around the world who deal with back pain and problems due to injury, age, or other factors.”
To learn more about SpinalCyte, LLC, please visit www.spinalcyte.com.
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company developing an innovative solution for spinal nucleus replacement using human dermal fibroblasts. Currently, SpinalCyte holds 21 U.S. and international issued patents, and has filed for an additional 43 patents pending. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement.
